Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Vaccinex's profit margin for the twelve months ending Dec 31, 2024 was -3100.5%. For fiscal 2024 it was -3100.5%, against -3552.8% the year before. The highest annual figure on record is -2486.7% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -3100.5% | +452.3 |
| FY2023 | Dec 31, 2023 | -3552.8% | +3652.6 |
| FY2022 | Dec 31, 2022 | -7205.5% | −4718.8 |
| FY2021 | Dec 31, 2021 | -2486.7% | +2129.5 |
| FY2020 | Dec 31, 2020 | -4616.2% | +1476.2 |
| FY2019 | Dec 31, 2019 | -6092.4% | −2015.3 |
| FY2018 | Dec 31, 2018 | -4077.1% | +16725.2 |
| FY2017 | Dec 31, 2017 | -20802.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -1584.0% | +22976.0 |
| Q3 FY2024 | Sep 30, 2024 | -11023.1% | −10120.9 |
| Q2 FY2024 | Jun 30, 2024 | -2427.2% | −170.3 |
| Q1 FY2024 | Mar 31, 2024 | -3747.1% | +5770.9 |
| Q3 FY2023 | Sep 30, 2023 | -24560.0% | −14148.0 |
| Q1 FY2023 | Mar 31, 2023 | -902.2% | −128.8 |
| Q4 FY2022 | Dec 31, 2022 | -2256.9% | −856.2 |
| Q3 FY2022 | Sep 30, 2022 | -9518.0% | −7626.4 |
| Q3 FY2021 | Sep 30, 2021 | -10412.0% | +24900.0 |
| Q1 FY2021 | Mar 31, 2021 | -773.4% | +8872.3 |
| Q3 FY2020 | Sep 30, 2020 | -1400.6% | +2954.5 |
| Q3 FY2019 | Sep 30, 2019 | -1891.6% | +1441.2 |
| Q2 FY2019 | Jun 30, 2019 | -35312.0% | −30067.6 |
| Q1 FY2019 | Mar 31, 2019 | -9645.7% | – |
| Q4 FY2018 | Dec 31, 2018 | -4355.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -3332.8% | – |
| Q2 FY2018 | Jun 30, 2018 | -5244.4% | – |
See a number that looks wrong?